ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

ASCO 2020: Genitourinary Cancers Highlights – Kidney and Bladder

OncoAlert (@oncoalert) • Instagram photos and videos

PDF) Critical Issues in Head and Neck Oncology

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Pembrolizumab plus axitinib in first-line continue to demonstrate superiority compared to sunitinib in patients with clear cell renal cell carcinoma - Onco Americas

Abeloff's Clinical Oncology [6 ed.] 0323476740, 9780323476744

PDF) Critical Issues in Head and Neck Oncology

ASCO GU 2021: Phase 3 Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib Monotherapy as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (CLEAR Study)

ASCO GU 2018: Safety and Efficacy of Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer

ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial - ScienceDirect

PDF) A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines